Claudia Caserta
Azienda Ospedaliera di Perugia(IT)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Glioma Diagnosis and Treatment, Urinary and Genital Oncology Studies
Most-Cited Works
- → Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma(2020)1,443 cited
- → First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial(2021)320 cited
- → Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab(2019)235 cited
- → Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications(2010)235 cited
- → Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up(2023)200 cited
- → Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis(2015)105 cited
- → Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.(2020)88 cited
- → AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma(2016)84 cited
- → Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme(2018)83 cited
- → Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial(2023)57 cited